Results 121 to 130 of about 40,707 (134)

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

European Journal of Cancer, 2017
Richard Joseph, Ralf Gutzmer, Lisa Kottschade   +2 more
exaly  

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Annals of Oncology, 2013
Bart Neyns, J D Wolchok, J D Wolchok
exaly  

Ipilimumab

Reactions Weekly, 2023
openaire   +1 more source

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013
James P Allison, Caroline Robert
exaly  

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of Oncology, 2016
MARESA Altomonte, Michele Del Vecchio, Sara Gandini   +2 more
exaly  

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Annals of Oncology, 2013
Michele Del Vecchio, Lorenza Di Guardo, Riccardo Danielli   +2 more
exaly  

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Proceedings of the National Academy of Sciences of the United States of America, 2015
Pierluigi Ballabeni, Emanuela Romano, Petra Baumgaertner   +2 more
exaly  

Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone

Cancer Biology and Therapy, 2017
Todd Schell, Kathleen Kokolus, Rogerio I Neves   +2 more
exaly  

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients

Journal of Dermatological Science, 2018
Taku Fujimura, Atsushi Ōtsuka, Yuki Yamamoto   +2 more
exaly  

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer

Lung Cancer, 2016
Jeffrey Crawford, Christopher Kelsey, Neal Ready   +2 more
exaly